文献速递胸部肿瘤放疗姑息放疗与转移瘤

双检查点免疫治疗联合消融放疗用于寡转移性非小细胞肺癌所有病灶:1b期试验的毒性与疗效结果

Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-12-08

这项1b期试验在最多6个颅外转移灶的寡转移性非小细胞肺癌患者中,对所有病灶行30至50 Gy分5次立体定向体部放疗(SBRT),放疗完成后7天开始双检查点免疫治疗(抗CTLA-4 tremelimumab联合抗PD-L1 durvalumab共4周期,后续durvalumab单药至进展或毒性)。17例入组中15例按方案接受至少1剂联合免疫治疗;3级及以上治疗相关不良事件见于6例(40%),仅1例可能与SBRT加入免疫治疗有关;中位无进展生存期(PFS)42个月,中位总生存期(OS)尚未达到。

要点

  • 所有转移灶SBRT(30至50 Gy分5次)联合双检查点免疫治疗的3级及以上治疗相关不良事件见于6例(40%)。
  • 6例3级及以上事件中仅1例可能与在免疫治疗基础上加入SBRT有关。
  • 中位PFS为42个月,中位OS尚未达到。

核心结论

  • 对所有转移灶行消融SBRT联合双检查点免疫治疗,与双检查点免疫治疗单药的历史研究相比未出现过高毒性率。
  • 研究未针对疗效进行把握度设计,但持久的PFS和OS结果提示该人群相较单用免疫治疗或单用放疗可能有潜在治疗获益。

研究设计与样本

  • 1b期临床试验,入组最多6个颅外转移灶的寡转移性非小细胞肺癌患者。
  • 所有病灶行SBRT,剂量30至50 Gy分5次。
  • 放疗完成后7天开始抗CTLA-4(tremelimumab)联合抗PD-L1(durvalumab)免疫治疗共4周期,后续durvalumab单药至进展或毒性。
  • 17例入组,其中15例按方案接受至少1剂联合免疫治疗。
  • 研究因COVID-19疫情期间入组缓慢而提前关闭(计划21例中入组17例)。

主要发现

  • 3级及以上治疗相关不良事件见于6例(40%),其中仅1例可能与在免疫治疗基础上加入SBRT有关。
  • 中位PFS为42个月。
  • 中位OS尚未达到。

局限性

  • 研究因COVID-19疫情期间入组缓慢而提前关闭(计划21例中入组17例)。
  • 研究未针对疗效进行把握度设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ablative local treatment of all radiographically detected metastatic sites in patients with oligometastatic non-small cell lung cancer (NSCLC) increases progression-free survival (PFS) and overall survival (OS). Prior studies demonstrated the safety of combining stereotactic body radiation therapy (SBRT) with single-agent immunotherapy. We investigated the safety of combining SBRT to all metastatic tumor sites with dual checkpoint, anticytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), and anti-programmed cell death ligand 1 (anti-PD-L1) immunotherapy for patients with oligometastatic NSCLC. METHODS AND MATERIALS: We conducted a phase 1b clinical trial in patients with oligometastatic NSCLC with up to 6 sites of extracranial metastatic disease. All sites of disease were treated with SBRT to a dose of 30 to 50 Gy in 5 fractions. Dual checkpoint immunotherapy was started 7 days after completion of radiation using anti-CTLA-4 (tremelimumab) and anti-PD-L1 (durvalumab) immunotherapy for a total of 4 cycles followed by durvalumab alone until progression or toxicity. RESULTS: Of the 17 patients enrolled in this study, 15 patients received at least 1 dose of combination immunotherapy per protocol. The study was closed early (17 of planned 21 patients) due to slow accrual during the COVID-19 pandemic. Grade 3+ treatment-related adverse events were observed in 6 patients (40%), of which only one was possibly related to the addition of SBRT to immunotherapy. Median PFS was 42 months and median OS has not yet been reached. CONCLUSIONS: Delivering ablative SBRT to all sites of metastatic disease in combination with dual checkpoint immunotherapy did not result in excessive rates of toxicity compared with historical studies of dual checkpoint immunotherapy alone. Although the study was not powered for treatment efficacy results, durable PFS and OS results suggest potential therapeutic benefit compared with immunotherapy or radiation alone in this patient population.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Bassetti MF, Morris BA, Sethakorn N, et al. Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 38072321. doi:10.1016/j.ijrobp.2023.11.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。